Challenges in Head and Neck Therapy for Malignant Neoplasm. The Paradigm Changes in XXI Century

Abrão Rapoport*, Ricardo Pires de Souza and Otávio Alberto Curioni

Department of Head and Neck Surgery and Otorhinolaryngology and Radiology of Hospital Heliópolis, São Paulo, Brazil

Introduction

The great majority (70%) of patients with head and neck cancer are diagnosed in stages III and IV. The new therapeutic paradigm is based on clinical stage, histopathological features (90% with squamous cell carcinoma), and new staging methods as PET-CT.

Considered that early stages (I and II) are diagnosed in 30% of cases, the best strategies are supported by surgery and or radiotherapy and for advanced stages, are indicated new schedules of chemotherapy plus irradiation, followed or not by salvage surgery and palliation regimens. Theses approaches led us for cross roads between choosing radical procedures or conservative managements, considering the Global Survival (GS) and the Free Disease Survival (FDS) as the Best parameter for therapeutic sucess [1,2].

1. General Director of Hospital Heliópolis, São Paulo, Brazil.
2. Radiologist of Hospital Heliópolis, São Paulo, Brazil.
3. Head of Head and Neck Department of Hospital Heliópolis, São Paulo, Brazil.

The mean age after 60 years old of head and neck cancer incidence, is mandatory in the stablishment of a new algorithm for the acceptance of The New Approach for Squamous Cell Carcinoma of the Head and Neck for the new century basing on:

The routinely use of PET-CT (Computed Tomography) before the beginning of the therapy

The PET-CT (Computed Tomography with Positron Emission) is indicated previously the therapy planning, in being in 30% of cases diagnosed in stages I/II and 70% for advanced stages III/IV. Based on theses facts, usually, the initial approach is conditioned for changes depending of this method, obliging the head and neck oncologist to review the historical results. For advanced stages, the chemotherapy association is followed by salvage surgery and palliation, allowing the increase of global survival of 6 to 12 months, not considering the cost augmentation of the schedule that cannot be supported by the Oncologic Health Program. Then, remains the question that is necessary the budget revision for the oncologic program, considering that the neoplasias usually course with failure results, and for these phases, we introduce new protocols of palliation where the patients are submitted to new drugs that allow a end of life without pain, and generation of quality of life [6-9].

Histopathology

The immunohistochemical method suggest genetic polimorphism, supporting the idea that non neoplastic tissue are affected and must be included in the field of treatment. Beside this fact, the Micro Tissue Array (MTA) allow the clinician to suggest routinely the association of chemoirradiation to limit the systemic spread of the neoplasia for distant organs [4].

For head and neck cancer, 90% of cases are diagnosed through hematoxilin eosin, and only in 10% is necessary the immunohistochemical method, considering that the SCC is diagnosed through its morphologic features.

For the remaining group (glandular tumors, sarcomas and indifferenitated carcinoma), tumoral cell markers are necessary to establish the best approach, where the oncogenes expression (EGF and other products as cyclooxygenase 2) are usually recommended as prognostic factors [5].

Elective Procedures

Surgery and or irradiation are the usual methods for the therapy in head and neck squamous cell carcinoma for stages I, II and eventually III. For stage IV, chemotherapy is usual in association with surgery and radiotherapy.

In spite of this algorithm, the successful of these procedures are limited, and in 60% of theses cases, it is necessary new approaches for the rescue of these patients. These neoplasias usually course with failure results, and for these phases, we introduce new protocols of palliation where the patients are submitted to new drugs that allow a end of life without pain, and generation of quality of life [6-9].

Future of Head and Neck Therapy

Considered that the diagnosis of head and neck cancer in early stages are unusual, for advanced cases, the majority of HNSCC are treated with therapeutic association to treat the elderly patients with comorbidities and the influence in global survival. The main question is concerned “how to handle with these groups of patients where is necessary the establishment of individual treatment considering the history and the real necessity of each one”.

*Corresponding author: Abrão Rapoport, Department of Head and Neck Surgery and Otorhinolaryngology and Radiology of Hospital Heliópolis, Rua Iramaia, 136 – Jardim Europa, São Paulo/SP – Brazil – CEP 01450-020, Tel: (+55 11) 289-6229; E-mail: arapoport@terra.com.br

Received April 24, 2014; Accepted April 26, 2014; Published May 03, 2014


Copyright: © 2014 Rapoport A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
These neoplasias usually course with failure, and for these phases, we introduce new protocols of palliation, where the patients are submitted to new drugs that allow end of life without pain.

References